BYAM REBECCA (Chief Financial Officer) purchased 8.5% of their position (39.06K shares) of HCW BIOLOGICS INC. on the open market
Open‑market purchase worth $68.1K — a moderate purchase. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 6/7/2023ACC: 0001209191-23-035121
Officer· Chief Financial Officer
Since Jul 2021
+39.06K
Net shares
Net buyer
$68.1K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
39.06K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+20K
Price / share
$1.67
Trade value
$33.34K
% of position
4.3%
6/5/2023
460.19K→480.19K
Common Stock
Direct
Shares
+19.06K
Price / share
$1.82
Trade value
$34.78K
% of position
4.0%
6/6/2023
480.19K→499.25K
Total
Net shares
+39.06K
Net value
$68.12K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/5/2023 | P · Purchase | +20K | $1.67 | $33.34K | 4.3% | 460.19K | 480.19K |
| Common Stock Direct | 6/6/2023 | P · Purchase | +19.06K | $1.82 | $34.78K | 4.0% | 480.19K | 499.25K |
| Total | +39.06K | $68.12K | ||||||
Derivative Transactions0
No derivative transactions reported